Current status of statin therapy for stroke prevention

References

• Minino AM, Xu J, Kochanek KD. Deaths: preliminary data from 2008. Natl Vital Stat. Rep.59(2), 1–72 (2010).
   PubMedGoogle Scholar
• Carroll K. Stroke incidence and risk factors in a population-based prospective cohort study. Health Stat. Quart.12, 18–26 (2001).
   Google Scholar
• Ramsay SE, Whincup PH, Wannamethee SG et al. Missed opportunities for secondary prevention of cerebrovascular disease in elderly British men from 1999 to 2005: a population-based study. J. Public Health29(3), 251–257 (2007).
   Google Scholar
• Lewington S, Whitlock G, Clarke R et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet370(9602), 1829–1839 (2007).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol.8(5), 453–463 (2009).
   PubMed Web of Science ®Google Scholar
• No authors listed. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet346(8991–8992), 1647–1653 (1995).
   PubMed Web of Science ®Google Scholar
• Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N. Engl. J. Med.320(14), 904–910 (1989).
   PubMed Web of Science ®Google Scholar
• Imamura T, Doi Y, Arima H et al. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke40(2), 382–388 (2009).
   PubMed Web of Science ®Google Scholar
• Adams HP Jr, Bendixxen BH, Kappelle LJ et al. Classification of subtype of acute ischaemic stroke. Stroke24, 35–41 (1993).
   PubMed Web of Science ®Google Scholar
• Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am. J. Epidemiol.134(3), 250–256 (1991).
   PubMed Web of Science ®Google Scholar
• O’Leary DH, Polak JF, Kronmal RA et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke23(12), 1752–1760 (1992).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Benavente O, Goldstein L et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke40, 1405–1409 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang X, Patel A, Horibe H et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int. J. Epidemiol.32(4), 563–572 (2003).
   PubMed Web of Science ®Google Scholar
• Noda H, Iso H, Irie F et al. Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study. Circulation119(16), 2136–2145 (2009).
   PubMed Web of Science ®Google Scholar
• Iribarren C, Jacobs DR, Sadler M, Claxton AJ, Sidney S. Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? The Kaiser Permanente Medical Care Program. Stroke27(11), 1993–1998 (1996).
   Web of Science ®Google Scholar
• Goldstein LB, Amarenco P, Szarek M et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study Neurology70, 2364–2370 (2008).
   PubMed Web of Science ®Google Scholar
• Labreuche J, Touboul PJ, Amarenco P. Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies. Atherosclerosis203(2), 331–345 (2009).
   PubMed Web of Science ®Google Scholar
• Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA300(18), 2142–2152 (2008).
   PubMed Web of Science ®Google Scholar
• Psaty BM, Anderson M, Kronmal RA et al. The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: the Cardiovascular Health Study. J. Am. Geriatr. Soc.52(10), 1639–1647 (2004).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis196(2), 489–496 (2008).
   PubMed Web of Science ®Google Scholar
• Chambless LE, Folsom AR, Davis V et al. Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987–1998. Am. J. Epidemiol.155(1), 38–47 (2002).
   PubMed Web of Science ®Google Scholar
• Stensland-Bugge E, Bonaa KH, Joakimsen O, Njolstad I. Sex differences in the relationship of risk factors to subclinical carotid atherosclerosis measured 15 years later: the Tromso study. Stroke31(3), 574–581 (2000).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Goldstein LB, Callahan A III et al. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis204(2), 515–520 (2009).
   PubMed Web of Science ®Google Scholar
• Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation109, III39–III43 (2004).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke35(12), 2902–2909 (2004).
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360(9326), 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet361(9364), 1149–1158 (2003).
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet364(9435), 685–696 (2004).
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA285(13), 1711–1718 (2001).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med.350(15), 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet360(9346), 1623–1630 (2002).
   PubMed Web of Science ®Google Scholar
• Williams B, Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. Br. Med. J.328(7440), 634–640 (2004).
   PubMed Web of Science ®Google Scholar
• Goldstein LB, Bushnell CD, Adams RJ et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke42(2), 517–584 (2011).
   PubMed Web of Science ®Google Scholar
• Yan B, Parsons M, McKay S et al. When to measure lipid profile after stroke? Cerebrovasc. Dis.19(4), 234–238 (2005).
   PubMed Web of Science ®Google Scholar
• Marti-Fabregas J, Gomis M, Arboix A et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke35(5), 1117–1121 (2004).
   PubMed Web of Science ®Google Scholar
• Jonsson N, Asplund K. Does pretreatment with statins improve clinical outcome after stroke?: a pilot case–referent study. Stroke32(5), 1112–1115 (2001).
   PubMed Web of Science ®Google Scholar
• Blanco M, Nombela F, Castellanos M et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology69(9), 904–910 (2007).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Goldstein LB, Szarek M et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke38(12), 3198–3204 (2007).
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J. Statins and stroke prevention. Cerebrovasc. Dis.24(2–3), 170–182 (2007).
   Google Scholar
• Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast Assessment of Stroke and Transient Ischaemic Attack to Prevent Early Recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol.6(11), 961–969 (2007).
   PubMed Web of Science ®Google Scholar
• Chroinin DN, Callaly EL, Duggan J et al. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin Population Stroke Study. Stroke42, 1021–1029 (2011).
   Google Scholar
• Luengo-Fernandez R, Gray AM, Rothwell PM. Effect of urgent treatment for transient ischaemic attack and minor stroke on disability and hospital costs (EXPRESS study): a prospective population-based sequential comparison. Lancet Neurol.8(3), 235–243 (2009).
   PubMed Web of Science ®Google Scholar
• Adams RJ, Albers G, Alberts MJ et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke39(5), 1647–1652 (2008).
   PubMed Web of Science ®Google Scholar
• Ovbiagele B, Hills NK, Saver JL, Johnston SC. Lipid assessment and treatment patterns in hospitalized TIA and ischemic stroke patients. J. Hosp. Med.1(4), 214–220 (2006).
   Google Scholar
• Ovbiagele B, Schwamm LH, Smith EE et al. Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke. Stroke41(7), 1508–1513 (2010).
   Google Scholar
• Lalouschek W, Lang W, Greisenegger S, Mullner M. Determination of lipid profiles and use of statins in patients with ischemic stroke or transient ischemic attack. Stroke34(1), 105–110 (2003).
   PubMed Web of Science ®Google Scholar
• Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke38(10), 2652–2657 (2007).
   PubMed Web of Science ®Google Scholar
• Benner JS, Tierce JC, Ballantyne CM et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics.22(Suppl. 3), 13–23 (2004).
   PubMed Web of Science ®Google Scholar
• Whitford DL, Hickey A, Horgan F, O’Sullivan B, McGee H, O’Neill D. Is primary care a neglected piece of the jigsaw in ensuring optimal stroke care? Results of a national study. BMC Fam. Pract.10, 27 (2009).
   PubMed Web of Science ®Google Scholar
• McGinnis B, Olson KL, Magid D et al. Factors related to adherence to statin therapy. Ann. Pharmacother.41(11), 1805–1811 (2007).
   PubMed Web of Science ®Google Scholar
• Adie K, James MA. Does telephone follow-up improve blood pressure after minor stroke or TIA? Age Ageing39(5), 598–603 (2010).
   PubMed Web of Science ®Google Scholar
• Joubert J, Reid C, Barton D et al. Integrated care improves risk-factor modification after stroke: initial results of the Integrated Care for the Reduction of Secondary Stroke model. J. Neurol. Neurosurg. Psychiatry80(3), 279–284 (2009).
   PubMed Web of Science ®Google Scholar